[go: up one dir, main page]

MX2018003850A - Moleculas de transporte de antigeno modular mejoradas y sus usos en animales. - Google Patents

Moleculas de transporte de antigeno modular mejoradas y sus usos en animales.

Info

Publication number
MX2018003850A
MX2018003850A MX2018003850A MX2018003850A MX2018003850A MX 2018003850 A MX2018003850 A MX 2018003850A MX 2018003850 A MX2018003850 A MX 2018003850A MX 2018003850 A MX2018003850 A MX 2018003850A MX 2018003850 A MX2018003850 A MX 2018003850A
Authority
MX
Mexico
Prior art keywords
molecules
animals
imat
module
prevention
Prior art date
Application number
MX2018003850A
Other languages
English (en)
Inventor
Rose Horts
Birte REICHE Dania-
Tammen Harald
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2018003850A publication Critical patent/MX2018003850A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/4359—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from fleas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Insects & Arthropods (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a proteínas recombinantes (aisladas), también denominadas como moléculas de MAT mejoradas (iMAT), que comprenden al menos un módulo de translocación, al menos un módulo de direccionamiento y al menos un módulo del antígeno, donde al menos un residuo de cisteína está sustituido con un residuo de aminoácido diferente. Tales moléculas de iMAT son útiles específicamente como vacunas, por ejemplo, para terapia y/o prevención de alergias y/o enfermedades infecciosas y/o prevención de la transmisión de enfermedades infecciosas en animales, con más preferencia rumiantes, cerdos, perros y/o gatos, pero excluyendo equinos. La presente invención también se refiere a los ácidos nucleicos que codifican tales moléculas de iMAT, vectores correspondientes y células o líneas celulares primarias.
MX2018003850A 2015-09-30 2016-09-27 Moleculas de transporte de antigeno modular mejoradas y sus usos en animales. MX2018003850A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15187810 2015-09-30
PCT/EP2016/072898 WO2017055235A1 (en) 2015-09-30 2016-09-27 Improved modular antigen transportation molecules and uses therof in animals

Publications (1)

Publication Number Publication Date
MX2018003850A true MX2018003850A (es) 2018-06-15

Family

ID=54266382

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003850A MX2018003850A (es) 2015-09-30 2016-09-27 Moleculas de transporte de antigeno modular mejoradas y sus usos en animales.

Country Status (10)

Country Link
US (2) US10898568B2 (es)
EP (1) EP3355917A1 (es)
JP (3) JP2018527395A (es)
KR (1) KR20180061338A (es)
CN (1) CN108136000B (es)
AU (1) AU2016333474A1 (es)
CA (1) CA2999930A1 (es)
EA (1) EA201890856A1 (es)
MX (1) MX2018003850A (es)
WO (1) WO2017055235A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943690A1 (en) 2014-03-31 2015-10-08 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof
US11013781B2 (en) 2015-07-01 2021-05-25 Alk-Abelló As Peptide combinations and uses thereof for treating grass allergy
CA2999930A1 (en) 2015-09-30 2017-04-06 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
US10556936B2 (en) 2016-05-27 2020-02-11 Alk Abelló Immunogenic proteins and fragments thereof from allergenic mites
JP6892079B2 (ja) * 2017-06-29 2021-06-18 京都府公立大学法人 制御性ｔ細胞誘導剤、アジュバント及び食品組成物
US20250009868A1 (en) 2021-07-13 2025-01-09 Intervet Inc. Overcoming antibody-interference in avians
CN113598072A (zh) * 2021-08-31 2021-11-05 云麻溯源生物科技(上海)有限公司 一种具有抑菌除臭功能的工业大麻猫砂及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
ES2152976T3 (es) 1993-02-26 2001-02-16 Immtech Internat Inc Proteina crp mutante, procedimientos y medios para su fabricacion y su utilizacion.
US20020169104A1 (en) 1997-05-01 2002-11-14 Glenn Frank Novel ectoparasite saliva proteins and apparatus to collect such proteins
JP3993035B2 (ja) 2001-07-19 2007-10-17 松下電器産業株式会社 データ記録方法、記録媒体、および再生装置
JP2004081210A (ja) * 2002-06-28 2004-03-18 Japan Science & Technology Corp システイン残基を改変したタンパク質からなる中空ナノ粒子およびそれを用いた薬剤
DE50209178D1 (de) 2002-10-11 2007-02-15 Imvision Gmbh Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen
EP1620554B1 (en) 2003-04-24 2008-01-23 Imvision GmbH Recombinant fel d 1 allergen
EP1621615B1 (en) * 2003-05-07 2010-03-17 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Method of purifying modified acarian main allergen
DE10359351A1 (de) 2003-12-16 2005-07-21 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden
WO2007065633A1 (en) 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
WO2009007418A1 (en) 2007-07-12 2009-01-15 Respiratorius Ab Novel bronchodilating isoquinoline amides
EP2083856B1 (en) 2007-08-15 2010-09-29 Circassia Limited Peptides for desensibilization against allergens
EP2222694B1 (en) * 2007-12-13 2014-01-15 Roche Diagnostics GmbH Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
JP5594691B2 (ja) * 2008-03-17 2014-09-24 独立行政法人理化学研究所 改変タンパク質
MX2010010353A (es) * 2008-03-25 2010-10-05 Bial Ind Farmaceutica S A Proteinas hibridas hipoalergenicas de los alergenos mayoritarios de acaros pertenecientes a los grupos 1 y 2 utiles para su utilizacion en el tratamiento de alergias.
SE535625C2 (sv) * 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
WO2012121395A1 (ja) 2011-03-09 2012-09-13 国立大学法人徳島大学 コレステロール依存性細胞溶解毒素の変異体及びそのddsへの利用
WO2012170842A2 (en) 2011-06-09 2012-12-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Peptide for protection of allergic respiratory disorders
FR2991996B1 (fr) * 2012-06-13 2016-07-08 Angany Genetics Methode de production d'allergenes recombinants de haute qualite par expression transitoire chez nicotiana benthamiana
IN2015DN03962A (es) * 2012-10-23 2015-10-02 Statens Seruminstitut
CA2943690A1 (en) * 2014-03-31 2015-10-08 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof
CA2999930A1 (en) 2015-09-30 2017-04-06 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals

Also Published As

Publication number Publication date
WO2017055235A1 (en) 2017-04-06
EA201890856A1 (ru) 2018-10-31
CA2999930A1 (en) 2017-04-06
CN108136000A (zh) 2018-06-08
JP2018527395A (ja) 2018-09-20
US20170087246A1 (en) 2017-03-30
JP2022009452A (ja) 2022-01-14
AU2016333474A1 (en) 2018-03-22
EP3355917A1 (en) 2018-08-08
JP2020023561A (ja) 2020-02-13
US20210128719A1 (en) 2021-05-06
KR20180061338A (ko) 2018-06-07
US10898568B2 (en) 2021-01-26
CN108136000B (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
MX2018003850A (es) Moleculas de transporte de antigeno modular mejoradas y sus usos en animales.
EA201691981A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение
MX383142B (es) Composiciones que comprenden polipéptidos que tienen actividad xilanasa y polipéptidos que tienen actividad arabinofuranosidasa.
MY175708A (en) Dna antibody constructs and method of using same
MX2023012264A (es) Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico.
TN2012000167A1 (en) Human il-23 antigen binding proteins
MX2015001675A (es) Proteinas de fusion de interleuquina 10 y usos de las mismas.
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
MX2019006633A (es) Formulaciones de anticuerpo.
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
NZ705370A (en) Fcγriib-specific fc region variant
MX2021010668A (es) Proteinas de fusion de citoquinas.
SG194755A1 (en) Pre-fusion rsv f antigens
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
UY34663A (es) Acido nucleico y proteina recombinante del gen de la endotoxina axmi345, vectores, células, composiciones y métodos para proteger plantas
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2014012977A (es) Anticuerpos anti-cd22.
WO2009117116A3 (en) Heat shock protein gp96 vaccination and methods of using same
MX356162B (es) Sistema de expresion y secrecion.
MX358963B (es) Polipeptidos con actividad proteasa.
MX2015010078A (es) Uso de polipeptidos con actividad proteasa en alimentos para animales.
EA201691004A1 (ru) Последовательность модифицированного эндолизина kz144
BR112014031882A2 (pt) uso de um polipeptídeo isolado, polipeptídeo, composição, polinucleotídeo isolado, construto de ácido nucleico ou vetor de expressão, célula hospedeira de expressão recombinante, métodos para produção de um polipeptídeo, para melhoria do valor nutricional de uma ração animal, e para o tratamento de proteínas, uso de pelo menos um polipeptídeo, aditivo de ração animal, ração animal, e, composição detergente
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine